Since the Supreme Court in June overturned Roe v. Wade, the court case that gave Americans the right to have an abortion, more women are turning to Plan B, the nation’s most widely recognized morning-after pill.
Although it is available over the counter, Plan B is not always accessible. At an average price of $40-$50, it is too expensive for many low-income people. Some states allow pharmacists to refuse to dispense it and retailers to keep the product out of reach of consumers.
Now, even more restrictions may be coming in the way of Plan B. The Food and Drug Administration’s labeling warns that the product “may prevent a fertilized egg from attaching to the womb” — a statement that scientists and medical professionals say is not supported by science. Evidence was included on the label to allow Plan B’s over-the-counter status. Many anti-abortion activists argue that any intervention with the egg is considered abortion; Medical professionals say otherwise.
Following the Supreme Court’s decision, Justice Clarence Thomas suggested that the court reconsider its past rulings on contraception. Confusion around label language can mean problems for the brand and its customers. So how will the future of Plan B?